AI assistant
LEAP THERAPEUTICS, INC. — Director's Dealing 2021
Jan 29, 2021
35080_dirs_2021-01-28_ff80cc7a-4915-4db6-b70c-2f94331636b7.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: LEAP THERAPEUTICS, INC. (LPTX)
CIK: 0001509745
Period of Report: 2021-01-26
Reporting Person: Sirard Cynthia (Chief Medical Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-01-26 | Employee Stock Option (Right to Buy) | $2.57 | A | 150000 | Acquired | 2031-01-25 | Common Stock (150000) | Direct |
| 2021-01-26 | Restricted Stock Units | $0 | A | 50000 | Acquired | Common Stock (50000) | Direct |
Footnotes
F1: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 36 equal monthly installments until the Option is fully vested, with the first such monthly installment vesting on the one month anniversary of January 26, 2021, the Vesting Start Date.
F2: The Restricted Stock Units were awarded pursuant to Leap's 2016 Equity Incentive Plan for no consideration. Restricted Stock Units will be settled in common stock.
F3: The Restricted Stock Units will cliff vest and be settled after three years of continuous service or upon a change of control of Leap, whichever is earlier.